Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis.

ABSTRACT:

Introduction

Biologic agents are used in patients with severe psoriasis who have not adequately responded to existing conventional systemic therapies. However, only a limited number of medical institutions in Japan are approved to use them, and their relatively high cost represents a substantial burden to patients. Apremilast is an oral phosphodiesterase-4 inhibitor approved in Japan for the treatment of psoriasis vulgaris in adult patients with an inadequate response to topical therapies and psoriatic arthritis in adult patients with active disease. To date, a large-scale real-world study of treatment patterns and costs associated with apremilast in Japan has not been conducted. The objective of this study was to assess whether apremilast can prolong time to first biologic therapy

SUBMITTER: Tanaka M 

PROVIDER: S-EPMC8850490 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature